Lifecore Biomedical, Inc.

NASDAQ:LFCR

Drug Manufacturers - Specialty & Generic

Healthcare
$6.40 +0.27%

+$0.02 today

Market cap
$242.60M
Beta
1.07
P/E (TTM)
-6.1
EPS (TTM)
-$0.91
52W Low $3.63High $8.98

Volume 0.15M

Average 0.29M

LFCR Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Lifecore Biomedical, Inc.NASDAQ: LFCR

Cost of Revenue · Q3 FY2026 · quarter ended Mar 2026

Cost of revenue of $18.73M in Q3 FY2026

Q3 FY2026 cost of revenue was $18.73M. Trailing-twelve-month cost of revenue was $93.03M. Over 3 fiscal years it compounded at +7.0% a year.

Context

  • Cost of revenue amounted to 68.7% of revenue in FY2025, up 1.4 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $18.73M or moves back toward the trailing-twelve-month quarterly average of $23.26M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$18.73M-34.3% QoQ
Last fiscal yearMay 2025
$88.57M+2.5% YoY
LTMMar 2026
$93.03M— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+2.5%——
3-year CAGR+7.0%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
88.57M USD
Year-over-year change
+2.5%
4-year CAGR
+9.4%

Cost of Revenue vs competitors

How LFCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Cost of revenue amounts to 68.8% of revenue for LFCR, versus a peer median of 28.9%.
LFCR Competitors
Cost of Revenue for LFCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGCCanopy Growth CorporationLTM Mar 2026CA$234.68M CAD+23.9%-0.9%75.1%
ACBAurora Cannabis Inc.LTM Mar 2026CA$134.79M CAD-13.4%+13.4%43.4%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$93.03M USD—+7.0%68.8%
IMMPImmutep LimitedFY2025A$61.41M AUD+47.8%+209.9%1217.6%
TKNOAlpha Teknova, Inc.LTM Mar 2026$27.87M USD-7.8%+4.2%66.7%
SGHTSight Sciences, Inc.LTM Mar 2026$11M USD-1.8%-4.7%13.8%
CVRXCVRx, Inc.LTM Mar 2026$8.55M USD-0.9%+18.5%14.5%
PRQRProQR Therapeutics N.V.LTM Mar 2026€1.38M EUR——10.3%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$111K USD———
BIOABioAge Labs, Inc.LTM Mar 2026$63K USD——0.6%
Peer median (excluding LFCR) —-1.3%+8.8%28.9%

Competitors are the stored peer set for LFCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
May 2021
FY2022
May 2022
FY2023
May 2023
FY2024
May 2024
FY2025
May 2025
Revenue100.87M111.27M103.27M128.26M128.87M
Cost of Revenue61.94M72.2M75.28M86.41M88.57M
Gross Profit38.94M39.07M27.99M41.85M40.3M
Gross Margin38.6%35.1%27.1%32.6%31.3%
Research & Development6.68M7.84M8.74M8.58M8.26M
Selling, General & Admin27.72M34.66M38.97M40.46M44.05M
Operating Expenses47.76M50.86M49.78M50.69M57.54M
Depreciation & Amortization19.87M18.06M13.18M8M8.03M
EBITDA(987K)12.84M(33.17M)35.6M(8.81M)
EBITDA Margin-1.0%11.5%-32.1%27.8%-6.8%
Operating Income(8.82M)(11.79M)(21.8M)(8.84M)(17.25M)
Operating Margin-8.7%-10.6%-21.1%-6.9%-13.4%
Interest Income48K81K68K00
Interest Expense8.93M15.55M17.65M18.09M21.84M
Other Income / Expenses(20.96M)(8.9M)(42.13M)18.36M(21.43M)
Income Before Tax(29.79M)(20.69M)(63.93M)9.51M(38.67M)
Pre-Tax Margin-29.5%-18.6%-61.9%7.4%-30.0%
Income Tax Expense(6.35M)(5.21M)308K183K43K
Net Income(32.29M)(116.72M)(99.56M)12.01M(38.72M)
Net Margin-32.0%-104.9%-96.4%9.4%-30.0%
EPS (Basic)(1.12)(3.97)(3.32)0.39(1.27)
EPS (Diluted)(1.12)(3.97)(3.32)0.33(1.27)
Weighted Avg Shares29.29M29.47M29.96M30.47M34.82M
Weighted Avg Shares (Diluted)29.29M29.47M29.96M36.66M34.82M

Lifecore Biomedical, Inc.

NASDAQ:LFCR

Intrinsic Alpha fair value

Locked

Current Price

$6.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.